Primary Outcome Measure:
- Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma. [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Follow the natural history of patients with thoracic malignancies. [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
- Conduct genomic, proteomic and immunological analyses on blood, tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic … [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
Eligibility Criteria
- Inclusion Criteria:
-
- Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET.
- Age greater than or equal to18 years. Children are excluded from the study, as the above thoracic malignancies are rare in this population.
- Ability of subject or the subject s Legally Authorized Representative to understand and the willingness to sign a written informed consent document.
- Exclusion Criteria:
- Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.
- Pregnant or breast feeding women will be eligible for this protocol, but will not undergo tumor biopsy.
- Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.
- HIV-positive patients on combination antiretroviral therapy are ineligible.
